

The impact of vitamin D supplementation in chronic heart failure

Submission date 25/06/2008	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 31/07/2008	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 22/05/2017	Condition category Circulatory System	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Klaus Witte

Contact details
Division of Cardiovascular and Diabetes Research
LIGHT building
University of Leeds
Leeds
United Kingdom
LS2 9JT
-
klauswitte@hotmail.com

Additional identifiers

Study information

Scientific Title
Examining the pleiotropic actions of vitamin D supplementation in patients with chronic heart failure

Study objectives

Chronic heart failure (CHF) is a condition characterised by symptoms of exercise intolerance due to shortness of breath and fatigue. Despite recent advances, patients suffer an inexorable decline in quality of life, have frequent hospital admissions, and a high yearly mortality rate. Cardinal features of CHF include heart muscle weakness (left ventricular dysfunction [LVSD]), muscle wasting and fatigue, neurohormonal activation with increased sympathetic activity, immune activation, insulin resistance, and peripheral vascular dysfunction with increased vascular resistance. In addition to its known effects on bone and mineral metabolism, vitamin D has recently been shown to be important in normal muscle function (both heart and skeletal muscle), control of immune function, insulin production and release and arterial relaxation, and low vitamin D levels are associated with high parathyroid levels which contribute to renal failure and salt imbalance. CHF patients are frequently vitamin D deficient, which might contribute to their ongoing symptoms. We want to find out if supplementing vitamin D deficient CHF patients with high-dose vitamin D for 12 months improves their heart function, quality of life, exercise tolerance, immune activation renal function and peripheral vascular function.

On 17/04/2012 the following changes were made to the trial record:

1. The anticipated end date was changed from 31/12/2012 to 01/05/2012 and the trial is in follow-up phase.
2. The sources of funding field was updated. The previous text was 'British Heart Foundation (BHF) (UK) - application in progress; National Institute for Health Research (NIHR) (UK) - Clinical Scientist Award for Applied Clinical Research: application in progress'

Ethics approval required

Old ethics approval format

Ethics approval(s)

Leeds West Research Ethics Board approval pending, date of submission 17/07/2008, ref: 08/H1307/94

Study design

Double-blind randomised placebo-controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Chronic heart failure

Interventions

100 µg vitamin D or placebo per day for 12 months

Intervention Type

Supplement

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Vitamin D supplementation

Primary outcome(s)

Left ventricular function, assessed by cardiac magnetic resonance at baseline and 12 months

Key secondary outcome(s)

1. Symptom status (New York Heart Association status), measured at baseline, 1, 4, 8 and 12 months
2. Exercise tolerance, measured at baseline and 12 months
3. Quality of life (Minnesota living with heart failure questionnaire, European Quality of Life instrument [EQ5D] and a 19-item Likert scale index [CASP-19]), measured at baseline, 1, 4, 8 and 12 months
4. Flow-mediated dilatation, measured at baseline and 12 months
5. Immune status, measured at baseline and 12 months
6. Insulin resistance, measured at baseline and 12 months
7. Autonomic activation, measured by heart rate variability at baseline and 12 months
8. Renal function, measured at baseline, 1, 4, 8 and 12 months
9. B-type natriuretic peptide (BNP), measured at baseline, 1, 4, 8 and 12 months

Completion date

01/05/2012

Eligibility

Key inclusion criteria

1. Class II and III heart failure due to left ventricular systolic dysfunction (left ventricular ejection fraction less than or equal to 40%)
2. Stable symptoms for 3 months on maximally tolerated medical therapy with no recent change in medication
3. Able to give informed written consent
4. Aged greater than 18 years, both sexes

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Currently taking (or have taken in the previous 3 months) calcium or other vitamin supplements

2. Currently prescribed amlodipine or other calcium channel antagonists (intake of spironolactone will be recorded)
3. CHF due to untreated valvular heart disease
4. History of primary hyperparathyroidism, sarcoidosis, tuberculosis or lymphoma
5. Vitamin D levels greater than 50 nmol/l

Date of first enrolment

01/01/2009

Date of final enrolment

01/05/2012

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

University of Leeds

Leeds

United Kingdom

LS2 9JT

Sponsor information

Organisation

University of Leeds (UK)

ROR

<https://ror.org/024mrx33>

Funder(s)

Funder type

Other

Funder Name

Josephine Lansdell Trust via the British Medical Association (BMA) (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration